Literature DB >> 33502649

A study of hydrophobins-modified menaquinone-7 on osteoblastic cells differentiation.

Hengfang Tang1,2, Zhu Zhu1,2, Zhiming Zheng3,4, Han Wang1, Chu Li1, Li Wang1, Genhai Zhao1, Peng Wang5,6.   

Abstract

Menaquinone-7 is involved in bone metabolism and can be used to prevent and treat osteoporosis. However, as a fat-soluble vitamin, menaquinone-7 has poor water solubility. As a surfactant, hydrophobins can change the affinity/hydrophobicity of the covered interface. In this study, menaquinone-7 was modified by hydrophobins, and the different addition ratios were explored. Moreover, Fourier transform infrared (FTIR), X-ray photoelectron spectroscopy (XPS), and water contact angle (WCA) measurements indicated that hydrophobins effectively bind to menaquinone-7 and greatly increase the hydrophilicity of the surface of menaquinone-7. Studies on the metabolism of MC3T3-E1 cells showed that compared with native menaquinone-7, HGFI-modified menaquinone-7 can significantly promote osteoblast differentiation but inhibit osteoclast differentiation. Besides, the Mito-Tracker Green experiments show that HGFI-modified menaquinone-7 can significantly promote the activity of mitochondria in cells. These findings indicate that hydrophobins can be used as an effective biomaterial to modify menaquinone-7, promote the formation of osteoblasts, and better to bone balance.

Entities:  

Keywords:  Alkaline phosphatase; Hydrophobins; Menaquinone-7; Mitochondria; OPG/RANKL; Osteocalcin

Mesh:

Substances:

Year:  2021        PMID: 33502649     DOI: 10.1007/s11010-021-04062-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  33 in total

Review 1.  Nanosuspensions: a promising drug delivery strategy.

Authors:  V B Patravale; Abhijit A Date; R M Kulkarni
Journal:  J Pharm Pharmacol       Date:  2004-07       Impact factor: 3.765

Review 2.  Pharmacogenetics and drug development: the path to safer and more effective drugs.

Authors:  Allen D Roses
Journal:  Nat Rev Genet       Date:  2004-09       Impact factor: 53.242

3.  Hydrophilic modification of polystyrene with hydrophobin for time-resolved immunofluorometric assay.

Authors:  Zefang Wang; Yujian Huang; Shan Li; Haijin Xu; Markus B Linder; Mingqiang Qiao
Journal:  Biosens Bioelectron       Date:  2010-08-26       Impact factor: 10.618

Review 4.  Hydrophobins: the protein-amphiphiles of filamentous fungi.

Authors:  Markus B Linder; Géza R Szilvay; Tiina Nakari-Setälä; Merja E Penttilä
Journal:  FEMS Microbiol Rev       Date:  2005-02-21       Impact factor: 16.408

Review 5.  Regulation of bone remodeling by vitamin K2.

Authors:  V D Myneni; E Mezey
Journal:  Oral Dis       Date:  2017-04-05       Impact factor: 3.511

6.  Effect of vitamin K2 on cortical and cancellous bone mass and hepatic lipids in rats with combined methionine-choline deficiency.

Authors:  Jun Iwamoto; Azusa Seki; Yoshihiro Sato; Hideo Matsumoto; Tsuyoshi Takeda; James K Yeh
Journal:  Bone       Date:  2011-02-23       Impact factor: 4.398

7.  Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials.

Authors:  Z-B Huang; S-L Wan; Y-J Lu; L Ning; C Liu; S-W Fan
Journal:  Osteoporos Int       Date:  2014-12-17       Impact factor: 4.507

8.  Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells.

Authors:  T Maeda; A Matsunuma; T Kawane; N Horiuchi
Journal:  Biochem Biophys Res Commun       Date:  2001-01-26       Impact factor: 3.575

9.  Dietary vitamin K2 supplement improves bone status after lung and heart transplantation.

Authors:  Liv Forli; Jens Bollerslev; Svein Simonsen; Gunhild A Isaksen; Kari E Kvamsdal; Kristin Godang; Gaut Gadeholt; Are H Pripp; Oystein Bjortuft
Journal:  Transplantation       Date:  2010-02-27       Impact factor: 4.939

10.  Menaquinone-7 regulates gene expression in osteoblastic MC3T3E1 cells.

Authors:  Hironobu Katsuyama; Kiyofumi Saijoh; Takemi Otsuki; Masafumi Tomita; Masao Fukunaga; Shigeo Sunami
Journal:  Int J Mol Med       Date:  2007-02       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.